Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience by Grogan, M et al.
Martha Grogan, Morie Gertz, Arleigh McCurdy, Lindsey Roeker, Robert Kyle, Sudhir Kushwaha, Richard Daly, 
Joseph Dearani, Richard Rodeheffer, Robert Frantz, Martha Lacy, Suzanne Hayman, Christopher McGregor, 
Brooks Edwards, Angela Dispenzieri
Martha Grogan, Sudhir Kushwaha, Richard Rodeheffer, 
Robert Frantz, Brooks Edwards, Department of Cardiovascular 
Diseases, Mayo Clinic, Rochester, MN 55905, United States
Morie Gertz, Robert Kyle, Martha Lacy, Suzanne Hayman, 
Angela Dispenzieri, Division of Hematology, Mayo Clinic, 
Rochester, MN 55905, United States
Arleigh McCurdy, Department of Hematology, the Ottawa 
Hospital, University of Ottawa, Ottawa, ON K1H8L6, Canada
Lindsey Roeker, Department of Medicine, Brigham and Women’s 
Hospital, Boston, MA 02115, United States
Richard Daly, Joseph Dearani, Division of Cardiovascular 
Surgery, Mayo Clinic, Rochester, MN 55905, United States
Christopher McGregor, Department of Cardiothoracic Surgery, 
University College, London WC1E6BT, United Kingdom
Author contributions: Grogan M, Gertz M, McCurdy A, 
Roeker L, Edwards B and Dispenzieri A designed the research 
study and drafted and revised the manuscript; Kyle R, Kushwaha 
S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman 
S and McGregor C contributed to data collection and critically 
revised the manuscript.
Institutional review board statement: The Mayo Foundation 
Institutional Review Board approved this study.
Informed consent statement: Patients were not required to 
give informed consent because of observational, retrospective 
nature of the study.
Conflict-of-interest statement: The authors of this manuscript 
have no conflicts of interest to disclose pertinent to this research. 
Data sharing statement: No additional data available. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Martha Grogan, MD, Department of 
Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, 
Rochester, MN 55905, United States. grogan.martha@mayo.edu
Telephone: +1-507-2843681
Fax: +1-507-2660103
Received: January 25, 2016
Peer-review started: January 27, 2016
First decision: February 29, 2016
Revised: March 20, 2016
Accepted: April 7, 2016
Article in press: April 11, 2016
Published online: June 24, 2016
Abstract
AIM: To determine the outcome of orthotopic heart 
transplantation (OHT) in immunoglobulin light chain 
(AL) amyloidosis.
METHODS: The medical records of patients with AL 
who underwent orthotopic heart transplantation at 
the Mayo Clinic in Rochester Minnesota from 1992 to 
2011 were reviewed. Patients met at least one of the 
following at: New York Heart Association class Ⅳ heart 
failure, ventricular thickness > 15 mm, ejection fraction 
< 40%. Selection guidelines for heart transplant 
included age < 60 years, absence of multiple myeloma 
and significant extra-cardiac organ involvement. 
Baseline characteristics including age, gender, organ 
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involvement, and New York Heart Association functional 
class were recorded. Laboratory data, waiting time 
until heart transplant, and type of treatment of the 
underlying plasma cell disorder were recorded. Survival 
from the time of OHT was calculated using Kaplan-
Meier survival curves. Survival of patients undergoing 
OHT for AL was compared to that of non-amyloid 
patients undergoing OHT during the same time period.
RESULTS: Twenty-three patients (median age 53 
years) with AL received OHT. There were no deaths in 
the immediate perioperative period. Twenty patients 
have died post OHT. For the entire cohort, the median 
overall survival was 3.5 years (95%CI: 1.2, 8.2 years). 
The 1-year survival post OHT was 77%, the 2-year 
survival 65%, and the 5-year survival 43%. The 5-year 
survival for non-amyloid patients undergoing OHT 
during the same era was 85%. Progressive amyloidosis 
contributed to death in twelve patients. Of those without 
evidence of progressive amyloidosis, the cause of death 
included complications of autologous hematopoietic 
stem cell transplantation for 3 patients, post-transplant 
lymphoproliferative disorder for 2 patients; and for 
the remaining one death was related to each of the 
following causes: acute rejection; cardiac vasculopathy; 
metastatic melanoma; myelodysplastic syndrome; and 
unknown. Eight patients had rejection at a median of 1.8 
mo post OHT (range 0.4 to 4.9 mo); only one patient 
died of rejection. Median survival of seven patients who 
achieved a complete hematologic response to either 
chemotherapy or autologous hematopoietic stem cell 
transplantation was 10.8 years. 
CONCLUSION: Our data demonstrate that long term 
survival after heart transplant is feasible in AL patients 
with limited extra-cardiac involvement who achieve 
complete hematologic response. 
Key words: Heart transplantation; Autologous stem cell 
transplantation; Amyloidosis; Chemotherapy; Heart 
failure
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Core tip: Heart failure due to immunoglobulin light 
chain (AL) amyloidosis is a devastating disease with 
poor prognosis. Orthotopic heart transplantation (OHT) 
is controversial. Twenty-three patients with AL amyloid 
underwent OHT at our institution over a twenty-year 
period. Median survival was 3.5 years following OHT. 
Median survival of seven patients who achieved a 
complete hematologic response to treatment for AL 
was almost 11 years. This study demonstrates that 
long term survival after heart transplant is feasible in 
AL patients with limited extra-cardiac involvement who 
achieve complete hematologic response. 
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INTRODUCTION
Immunoglobulin light chain (AL) amyloidosis is a syste­
mic plasma cell disorder, characterized by the pro­
duction of a kappa or lambda monoclonal light chain 
by a clonal population of bone marrow plasma cells[1]. 
The monoclonal light chain misfolds into an insoluble 
beta­pleated sheet conformation. The aberrant protein 
subsequently accumulates in tissues, leading to organ 
dysfunction.
Cardiac involvement occurs in 50% of patients with 
systemic AL amyloidosis and is the most important risk 
factor for adverse prognosis and death[2,3]. Amyloid fibrils 
infiltrate the extracellular space of the valves, atria and 
ventricles, as well as the perivascular spaces, resulting 
in biventricular wall thickening without ventricular dila­
tion[4]. As a result, atrial pressure increases, and atrial 
dilation occurs despite amyloid infiltration. Clinical fea­
tures of cardiac amyloidosis include restrictive physio­
logy, heart failure, dysrhythmias, and sudden cardiac 
death[1,4,5]. In addition, there is evidence suggesting that 
the immunoglobulin free light chains are toxic to the 
myocardium[6].
Patients with advanced heart failure due to AL have 
an extremely poor prognosis and often do not survive 
long enough to benefit from therapy for amyloidosis. 
Orthotopic heart transplantation (OHT) in AL has 
been limited due to the risk of disease progression in 
other organs and recurrence of amyloid deposition 
in the transplanted heart[7,8]. Although earlier studies 
suggested inferior outcomes of OHT for compared 
with non­amyloid indications[8,9], more recent reports 
have found survival similar to other forms of heart 
failure[10]. Controversy regarding the role of OHT in AL 
remains[11,12] and many centers consider amyloidosis to 
be a contraindication to OHT. The purpose of the current 
study was to determine the long term outcome and 
predictors of survival in a large single­center cohort of 
patients undergoing OHT for AL.
MATERIALS AND METHODS
Study population
Patients were identified from our institutional database 
of cardiac transplantation recipients. The diagnosis of 
amyloidosis was confirmed by demonstrating Congo 
red positivity in tissue samples. AL amyloid was 
confirmed by laser dissection mass spectrometry in 
all but two patients, who had typing performed by 
immunohistochemistry. During the period from May 
31, 1992 to December 31, 2011, 3117 patients with 
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AL amyloidosis were seen at the Mayo Clinic. Twenty­
one percent (668 patients) had overt congestive heart 
failure. One hundred and thirty­seven were referred 
for OHT evaluation, and 77 patients completed their 
evaluation for OHT. Of those completing the evaluation, 
33 were deemed ineligible for OHT. Reasons for 
ineligibility included extensive amyloid in 29 and one 
instance of each of the following: Coexisting myeloma; 
coexisting lymphoma; improving cardiac status due to 
chemotherapy; and lack of financial approval. Forty­
four patients (7% of patients with overt heart failure) 
completed evaluation and were listed for OHT, but only 
23 were transplanted. Twenty­one were removed from 
the listing for the following reasons: Death (n = 12); 
further medical decline (n = 5); patient refusal (n = 2); 
myeloma (n = 1); and transplant elsewhere (n = 1). 
The median time to de­listing was 48 d (interquartile 
range 14, 111 d; range 0­341 d). 
Throughout the 20­year period, all patients met at 
least one of the following at time of listing: New York 
Heart Association class Ⅳ heart failure, ventricular 
thickness > 15 mm, ejection fraction < 40%. In 1998, 
additional selection guidelines were added: Age < 60 
years; combination of the urine light chain, serum 
monoclonal protein and bone marrow plasmacytosis 
that does not infer the presence of multiple myeloma or 
related disorders including low bone marrow plasma cell 
labeling index; absence of renal involvement as defined 
by a 24­h urine total protein excretion of < 500 mg and 
creatinine clearance > 50 mL/min per square meter 
unless combined renal transplant planned; absence of 
liver involvement ­ if elevation of alkaline phosphatase 
was thought to be due to heart failure, liver biopsy 
was to be done to exclude interstitial amyloid deposits. 
The presence of vascular deposits in a biopsy of the 
rectum, fat or viscera was not an exclusionary criterion. 
Assignment of organ involvement was according to 
the consensus criteria from the 10th International 
Symposium on Amyloid and Amyloidosis[13]. The modi­
fied body mass index (mBMI) was calculated as BMI 
multiplied by serum albumin level in gram per litre. 
For most patients the values used for listing and pre­
operative BMI (and mBMI) were the same given the 
proximity of listing to OHT.
The autologous hematopoietic stem cell trans­
plantation (AHSCT) protocol is as previously described, 
and 11 of the patients have been previously reported[14]. 
Demographic, clinical and laboratory data were collected 
from the Mayo Clinic Transplant Center database, the 
Robert A Kyle Dysproteinemia database, and all medical 
records were reviewed. Because most of these patients 
were treated before era of the serum immunoglobulin 
free light chain assay, the ability to assign a hematologic 
response was limited. The determination of hematologic 
response was a hybrid of the two consensus guidelines. 
If patients had serum immunoglobulin free light chains 
measured (n = 9), then the 2012 consensus response 
criteria were applied[15]; otherwise, the 10th consensus 
response criteria from the International Symposium 
on Amyloid and Amyloidosis were applied[13]. Two 
patients had measurable M­spikes, 8 had positive immu­
nofixation of the serum or urine that could be followed, 
and 4 either had none of the aforementioned detected 
(or testing not performed prior to starting chemo­
therapy).
Immunosuppression 
Post OHT, all patients received standard therapy for 
immunosuppression, according to our institutional 
protocol at the time of transplant. The first twenty­one 
patients received OKT3, cyclosporine, prednisone, and 
azathioprine or mycophenate mofetil. A gradual taper 
of cyclosporine was done over the first year to baseline 
immunosuppression. Surveillance endomyocardial 
biopsies to monitor for rejection were used to help 
guide prednisone taper. The last two patients received 
prednisone, mycophenate mofetil, and tacrolimus.
Statistical analysis
Medical records for the patients undergoing OHT for AL 
amyloidosis were reviewed. Survival from the time of 
OHT was calculated using Kaplan­Meier survival curves. 
Comparison of survival curves was done with the log­
rank test. Baseline variables were tested for their impact 
on overall survival using Cox proportional modeling. The 
database was closed to follow up as of March 18, 2015. 
All statistics were calculated using JMP 10.0.0 (SAS, 
Carey, North Carolina). 
RESULTS
Twenty­three patients with AL amyloidosis underwent 
OHT (Table 1). Fifty­two percent were female (n = 12), 
and all but two were Caucasian. Twenty­one patients 
had isolated cardiac involvement at baseline clinical 
evaluation; one patient (OHT#14) had mild peripheral 
nerve and gastrointestinal involvement, and one (OHT 
#15) had peripheral nerve involvement. Twenty­two 
patients had had a clonal lambda plasma cell disorder; 
one had a kappa clone. Three patients had renal 
transplantation, one simultaneous with the OHT and the 
others at 23 and 53 mo post OHT. 
Twenty patients have died post OHT (Table 1 and 
Figure 1A). The baseline disease burden is outlined in 
Table 2. For the entire cohort, the median overall survival 
was 3.5 years (95%CI: 1.2, 8.2 years). The 1­year 
survival post OHT was 77%, the 2­year survival 65%, 
and the 5­year survival 43% (Figure 1A). Progressive 
amyloidosis contributed to death in twelve patients. Of 
those without evidence of progressive amyloidosis, the 
cause of death included post­AHSCT complications for 
3 patients, post­transplant lymphoproliferative disorder 
for 2 patients; and for the remaining there was one 
death related to each of the following causes: Acute 
rejection; cardiac vasculopathy; metastatic melanoma; 
myelodysplastic syndrome; and unknown. Eight patients 
had rejection at a median of 1.8 mo post OHT (range 0.4 
to 4.9 mo); only one patient died of rejection). 
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Table 1  Demographics and orthotopic heart transplantation outcomes
AL-OHT M/F Age at OHT List to OHT (d) Year OHT PO FU (yr) Major outcomes
8 F 52     62 1997 16.5 Alive, doing well
22 F 53 1160 2011   3.9 Alive, PTLD in remission, VGPR on bortezomib
23 M 58     13 2011   3.1 Alive, doing well
1 M 45     86 1992 14.1 Died, progressive amyloid; renal transplantation 53 mo post OHT
17 F 51     94 2003 10.8 Died, renal failure, debility; hematologic relapse and renal 
amyloid
9 M 56     16 1998   8.6 Died, metastatic melanoma
2 M 44   126 1993   8.4 Died, PTLD, sepsis, progressive amyloidosis 
12 F 57     44 1999   8.2 Died, cardiogenic shock secondary to cardiac amyloid, required 
dialysis for renal amyloid post ASHCT#2
3 M 56     14 1994   7.5 Died, progressive amyloid
14 M 33     30 1999   6.3 Died, cardiac allograft vasculopathy
16 F 53     33 2000   5.4 Died, progressive GI amyloid and stroke; renal transplant 23 mo 
post-op
7 M 61   415 1997   3.5 Died, progressive amyloid autonomic and peripheral neuropathy
18 M 56     33 2004   3.1 Died, complications of myelodysplastic syndrome
5 F 47     68 1995   2.6 Died, PTLD, progressive multifocal leukoencephalopathy
10 F 54       5 1998   2.2 Died, progressive amyloid
19 M 62     18 2005   2.1 Died, progressive amyloid peripheral neuropathy and GI 
involvement, recurrent pneumonia
4 M 49     86 1994   1.2 Died, progressive amyloid
21 F 51     29 2007   1.2 Died, progressive GI amyloid, right heart failure, renal failure, 
steroid myopathy vs amyloid neuropathy
13 F 51   103 1999   0.9 Died, sepsis, multiorgan failure after AHSCT
11 F 48     31 1999   0.7 Died, disseminated fungal infection after AHSCT
15 F 60     33 1999   0.6 Died, progressive amyloid peripheral and autonomic neuropathy
20 F 52     33 2006   0.6 Died, progressive amyloid and overwhelming infection
6 M 56     99 1996     0.04 Died, refractory rejection; had combined renal and cardiac 
transplant
Median (IQR) 53 (33, 62) 33 (29, 94)
The first three rows are alive. M: Male; F: Female; PO FU: Post-operative follow-up; PTLD: Post-transplant lymphoproliferative disorder; GI: 
Gastrointestinal; VGPR: Very good partial response; IQR: Interquartile range. 
Table 2  Baseline disease burden
AL-OHT IFE positive g/dL dFLC (mg/L) Tx mBMI, kg 
g/L m2
Creatinine (mg/
dL)
Alkaline phosphatase 
(U/L)
IVS (mm) EF (%) BM PC (%)
8 Yes   688 0.9 115 15 33 12
22 Yes    1.6   298   977 0.8   60 14 55 18
23 NA 0 1059   951 1.5 150 15 50 10
1 Yes 1120 1.4 112 16 40   8
17 Yes 0     70   913 0.9 302 16 64 12
9 Yes 0   271   822 1.7 334 12 78   8
2 Yes 1191 1.1 130 15 60   5
12 Yes 0   742 1.2 312 17 30 13
3 NA   729 1.2 18 56 20
14 Yes   620 0.9 207 16 20 12
16 No 0   402 1.1 145 12 53 15
7 No 1.2 132 15 57   6
18 Yes 0   245   935 1.2   90 18 56 17
5 No   599 0.9 428 22 40   4
10 Yes 0   629 0.7 110 16 44   5
19 Yes 0   304   744 1.1   90 16 24 12
4 NA   693 1.1 14 20 NA
21 Yes    1.9   138   632 0.9   70 13 43 13
13 Yes      0.14   779 1.0 312 16 40   5
11 Yes 0   279   513 0.7 156 21 30 12
15 Yes   788 1.2 118 17 50   9
20 Yes 0     87   865 1.5 112 14 40   7
6 Yes   894 1.1 229 13 35 19
Median (IQR) 27 (11-30) 761 (631, 919) 1.1 (0.9, 1.2) 132 (111, 267) 15 (14, 16) 40 (34, 56) 12 (7, 13)
The first three rows are alive. IFE: Immunofixation of serum and/or urine; dFLC: Difference between involved and uninvolved immunoglobulin free light 
chains; Tx: Transplant; mBMI: Modified body mass index [albumin × weight/(height)2]; IVS: Interventricular septum; EF: Ejection fraction; BM PC: Bone 
marrow plasma cells; NA: Not available; IQR: Interquartile range.
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Figure 1B shows a comparison of this cohort to 
patients undergoing isolated OHT at our center for 
non­ amyloid indications, where 1 year overall survival 
is 94.8% ± 2.1% and 5­year survival 85.2% ± 4.4%. 
Given the small sample size, it is difficult to assess 
baseline factors that might predict for early death. 
Notably, no patient died within the immediate OHT 
peri­operative period. On univariate analysis none of 
the following factors were significant risk factors for 
poor overall survival: Age, gender, BMI or mBMI (at 
listing or at transplant), time from listing to OHT, serum 
creatinine, or bone marrow plasmacytosis.
Figure 1C shows the comparison of patients with AL 
who underwent OHT with AL patients without and with 
overt heart failure who did not undergo OHT, and with 
those who were listed but did undergo OHT.
Three patients had no therapy (chemotherapy or 
AHSCT) for amyloidosis and only four received treatment 
prior to OHT (Table 3). Reasons for no chemotherapy/
AHSCT were: Inability to harvest stem cells for planned 
AHSCT; rejection two weeks after OHT; and death 7 
mo after OHT. One patient received chemotherapy only 
prior to OHT, 4 received chemotherapy pre­ and post­
OHT, and 15 only post­OHT. The non­AHSCT first line 
therapies are shown in Table 3. Therapies beyond first 
line therapies included bortezomib, AHSCT, melphalan 
with corticosteroids, or an IMiD with dexamethasone; 
one patient received doxorubicin.
After their first line therapy, seven patients achieved 
a complete hematologic response (CR), 3 a very good 
partial response, 2 a partial response, and 11 remained 
immunofixation positive or were not assessed before 
death (Table 3). As shown in Figure 2A, patients 
achieving a CR fared much better than those who did 
not, achieving a median survival of 10.8 years.
Thirteen patients underwent AHSCT, performed 
at a median of 8 mo (range 3­24 mo) post OHT with 
one patient having a second AHSCT 82 mo post OHT. 
In two patients AHSCT was planned but could not be 
performed due to inability to harvest stem cells. The 
median survival of those undergoing AHSCT was 6.3 
years (95%CI: 1.2, 8.6 years). Figure 2B demonstrates 
survival outcomes of those who received AHSCT vs 
those who did not. Among the patients who underwent 
AHSCT, 8 received full dose melphalan conditioning (200 
mg/m2), and 5 received attenuated doses. Two of the 
eight patients receiving full dose melphalan conditioning 
died within three years post AHSCT, and one is alive 
33 mo at last follow­up. In contrast 3 of the 5 receiving 
attenuated melphalan conditioning died within 3­year 
post AHSCT. For the 2 who died within 100 d of AHSCT, 
the cause of death was disseminated fungal infection 
in one and sepsis leading to multi­organ failure in the 
other. Four of the AHSCT patients achieved a CR, 5 a 
very good partial response (PR) or PR, and 4 no signi­
ficant response or not assessable.
Figure 1  Overall survival. A: Overall survival from orthotopic heart transplant; B: Overall survival comparing OHT for AL amyloidosis to OHT from 1992 to 
2011 for non-amyloid indications; C: Comparison of survival with non OHT subgroups. OHT: Orthotopic heart transplantation; CHF: Congestive heart failure; AL: 
Immunoglobulin light chain.
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DISCUSSION
Given the limited supply of donor hearts, OHT in AL 
amyloidosis remains controversial due to the risk of 
recurrent amyloidosis in the graft or progression of 
other organ involvement. This long term follow­up study 
reports the largest single center experience of OHT in 
AL. Our results support the use of OHT in AL amyloidosis 
patients with predominant cardiac involvement and no 
evidence of myeloma, especially if they have achieved (or 
are able to achieve) a complete hematologic response. 
Although the median overall survival of our cohort was 
only 3.5 years, those patients who achieved a complete 
hematologic response had a remarkably good overall 
median survival of more than 10 years. 
Superior survival is reported in patients with AL 
amyloidosis and cardiac involvement who undergo OHT 
compared to patients who do not[14,16]. In a report of 
14 patients from the United Kingdom, median overall 
survival was 7.5 years from OHT; in 8 patients who 
underwent AHSCT and OHT, survival was increased to 
9.7 years[17]. These data are confounded by selection 
Table 3  Chemotherapy and response
AL-OHT Rx relative to OHT First amyloid directed therapy (Rx) Response to1st Rx Lines of Rx
8 Only Rx post-OHT AHSCT1 CR 1
22 Rx pre- and post-OHT Mel-Dex CR ≥ 2
23 Rx pre- and post-OHT Bortezomib-Dex3 VGPR ≥ 2
1 Only Rx post-OHT Mel-Pred CR ≥ 2
17 Only Rx post-OHT AHSCT1 CR ≥ 2
9 Only Rx post-OHT AHSCT1 CR ≥ 2
2 Only Rx pre-OHT Mel-Pred IFE positive 1
12 Only Rx post-OHT AHSCT2 PR ≥ 2
3 Only Rx post-OHT AHSCT1 CR 1
14 Only Rx post-OHT AHSCT2 IFE positive 1
16 Only Rx post-OHT AHSCT1 VGPR ≥ 2
7 Rx pre- and post-OHT VBMCP IFE positive ≥ 2
18 Only Rx post-OHT AHSCT1 VGPR 1
5 Only Rx post-OHT Mel-Pred NA 1
10 No treatment None NA 0
19 Only Rx post-OHT AHSCT2 PR 1
4 Rx pre- and post-OHT Mel-Pred IFE positive ≥ 2
21 Only Rx post-OHT AHSCT2 No response ≥ 2
13 Only Rx post-OHT AHSCT1 IFE positive 1
11 Only Rx post-OHT AHSCT2 IFE positive 1
15 No treatment None NA 0
20 Only Rx post-OHT Dex CR 1
6 No treatment None NA 0
1Melphalan conditioning 200 mg/m2; 2Melphalan conditioning 140 mg/m2 in all but OHT #12 who got 150 mg/m2; 
3Patient had AHSCT as second line and received Melphalan conditioning 200 mg/m2. Amyloid directed therapy: 
AHSCT: Autologous hematopoietic stem cell transplant; Mel: Oral melphalan; Pred: Prednisone; Bortez: Bortezomib; 
Dex: Dexamethasone; VBMCP: Vincristine, BCNU, melphalan, cytoxan, prednisone; NA: Not available; CR: Complete 
hematologic response; PR: Partial response; VGPR: Very good partial response; IFE: Immunofixation. 
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Figure 2  Influence of chemotherapy on overall survival. A: Overall survival (OS) based on hematologic response. The median OS for the 11 non-responders/non-
evaluable patients was 1.2 years. The median OS for the 5 patients achieved VGPR or PR was 5.4 years. The median OS for the 7 patients achieving CR was 10.8 
years; B: OS based on whether or not patient received AHSCT. The median OS for the 10 patients not undergoing AHSCT was 2.4 years; the median OS For the 13 
patients undergoing AHSCT was 6.3 years. VGPR: Very good partial response; CR: Complete hematologic response; AHSCT: Autologous hematopoietic stem cell 
transplantation.
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biases, but the fact remains that 30%­40% of patients 
with AL amyloidosis die within the first 6 mo of their 
diagnosis due to cardiac causes[18] making consideration 
of aggressive strategies imperative. 
Most series of heart transplantation in AL have 
reasonable 1­year survival rates (Table 4). In our 
study there was no perioperative mortality. The major 
causes of death in our and other series are infection and 
progressive amyloidosis. If performed without chemo­
therapeutic support, 5­year survival is just 20%[19], 
Improved survival rates have been seen in patients who 
undergo AHSCT, with 1­ and 5­year survival of 82% and 
65% respectively in our earlier report[14]. Recent reports 
suggest improved short term outcomes with advances 
in chemotherapy and AHSCT, with the Stanford series 
reporting 1 year survival of 100%[20].
In the MGH series of 18 AL patients undergoing OHT 
approximately 60% of patients were alive at 6 years[10], 
and, in contrast to earlier studies[8,9,21], was similar to 
that of non­amyloid patients. Although overall survival 
in our study was reduced compared with patients 
transplanted for non­amyloid indications, our series 
includes many early era patients who did not receive the 
benefit of current therapy for amyloidosis. Nevertheless, 
the long term survival of the patients in our series 
who achieved complete hematologic response was 
remarkably good.
Selecting patients with primarily cardiac involvement 
in AL is challenging. Subclinical extra­cardiac organ 
involvement may progress post heart transplant to 
clinically important disease. Perivascular intestinal 
amyloid is common and not viewed as a barrier to 
cardiac transplantation. However, in our experience, 
patients with significant mucosal intestinal involvement 
do poorly and are often not able to tolerate aggressive 
treatment for AL. Clearly not all patients with cardiac 
involvement will require heart transplant; there are 
patients with significant cardiac involvement who can 
have cardiac improvement with effective chemotherapy 
alone[22­25]. Perhaps cardiac biomarkers like ST­2 may 
lend insight to those with irreparable damage despite 
effective chemotherapy[26].
“Better selection” also means choosing those 
patients in whom the underlying plasma cell clone can 
be controlled, since in our study and others effective 
chemotherapy has resulted in the best outcomes post­
OHT[10,16,20]. Most of the patients in our series did not 
receive chemotherapy prior to OHT because the only 
chemotherapies available at the time of their diagnosis 
were oral melphalan and prednisone and high dose 
melphalan with AHSCT. Newer treatment options[27], 
especially bortezomib containing regimens, are less 
myelosuppressive, making pre­OHT therapy a possibility. 
Furthermore, the improvement in chemotherapeutic 
regimens makes hematologic response more likely in 
the current era. 
Achieving a hematologic response pre­OHT is not a 
simple matter. Time is of the essence in these patients. 
In our experience and others, approximately 40% of 
AL patients listed do not undergo OHT either due to 
death or deterioration[10]. This seems to be related to 
both delayed diagnosis, as well as inability to support 
these patients with traditional heart failure therapy and 
devices. In the MGH series, patients with amyloidosis 
had a mortality hazard ratio of 4.7 (95%CI: 2.8, 11.8) 
as compared to non­amyloidosis patients while on the 
waiting list[10]. The only predictive factor of survival to 
OHT in that study was BMI ­ patients with lower BMI 
fared better than those with higher BMI, although this 
was not confirmed in our study.
The number of AL amyloid patients transplanted 
at our institution in recent years has declined. This 
reduction is multifactorial, and reflects patients receiving 
earlier and more effective bone marrow directed 
treatment, more rigorous selection, the availability of 
OHT for AL at other medical centers, and our own reluc­
tance to offer OHT after some discouraging outcomes. 
However, the excellent long term survival in this study of 
patients achieving CR , coupled with markedly improved 
short term survival recently reported[20] have prompted 
renewed enthusiasm for OHT in AL in highly selected 
patients.
We recognize that our study is limited by being a 
small series of highly selected patients, lacking currently 
available cardiac biomarkers and modern markers 
of clonal burden and access to current treatment 
regimens. Despite these limitations, in carefully selected 
patients, long term survival can be achieved. Moving 
forward the challenge will continue to be the selection 
of the appropriate patients. The patients likely to derive 
the most benefit are those who: (1) have plasma cells 
that are responsive to chemotherapy; (2) have clinically 
significant involvement of the heart only; and (3) are 
Table 4  Orthotopic heart transplantation in patients with 
amyloidosis
Ref. n AHSCT Outcomes
Current series 23 13 1-yr OS 77%
5-yr OS 43%
MGH[10] 18 14 5-yr OS 60%
United Kingdom 2004[19]  171   3 1-yr 59%
5-yr approximately 37%
United Kingdom 2010[17]  141   8 1-yr OS 86%
5-yr OS 45%
Spanish registry[28] 13   3 1-yr OS 43%
5-yr OS 36%
German group[29] 12   5 1-yr OS 83%
3-yr OS 83%
ISHLT Registry[8,30]  102 None 1-yr 88%
4-yr 38%
Maurer[16] 10   8 1-yr 90%
Stanford[20]   9   5 1-yr 100%
French registry[31]   8   3 1-yr 89%
1Unclear how much overlap between these two groups. Intervals for 
Dubrey series was 1982-2002 and for Sattianayagam series, interval 
was 1984-2004, but there was no reference of which patients had been 
previously reported; 2At least 8 were AL; unclear what other 2 were. ISHT: 
International Society for Heart Transplant; OS: Overall survival; AHSCT: 
Autologous hematopoietic stem cell transplantation.
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not demonstrating significant cardiac response despite 
effective chemotherapy. The current lack of effective 
short term cardiac support and the rapidly progressive 
nature of AL cardiac amyloidosis warrant consideration 
of revised guidelines for organ allocation in these 
patients. 
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Background
Cardiac involvement is present in approximately 50% of patients with 
immunoglobulin light chain (AL) amyloidosis amyloidosis and is associated 
with a dismal prognosis. Heart transplant for AL amyloid is controversial, due to 
concerns about amyloid deposition in the transplanted heart and the potential 
for increased morbidity and mortality from the underlying plasma cell disorder.
Research frontiers
The research goal was to review a single center experience with cardiac 
transplantation for AL amyloid and determine outcome.
Innovations and breakthroughs
This study demonstrates that long term survival is possible in highly selected 
patients with AL amyloid who undergo cardiac transplantation if the underlying 
plasma cell disorder can be controlled. 
Applications 
Patients with cardiac AL amyloid and limited extra cardiac involvement may be 
considered for cardiac transplantation. Long term survival is possible in those 
who achieve a complete hematologic response to chemotherapy or autologous 
stem cell transplantation.
Terminology
Immunoglobulin light chain AL is a plasma cell disorder which results in 
deposition of amyloid fibrils in the organs and tissues of the body. Autologous 
hematopoietic stem cell transplantation is a strategy to treat the underlying 
plasma cell disorder that causes AL amyloidosis.
Peer-review
The authors presented a good overview of patients with AL amyloidosis + 
advanced heart failure who received cardiac transplantation.
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